glp 1 and glp 2 drugs Comparing Ozempic, Wegovy Other GLP-1 MCT2D | The Benefits of

In summary, GLP-1 RAs represent a promising therapeutic option for obese patients with HFpEF, but their large-scale adoption will require further evidence of efficacy, safety, and long-term benefits through rigorous and well-designed clinical trials

Causes of obesity: a review

GLP-1 RAs, particularly semaglutide, have been shown to reduce liver steatosis and improve markers of liver inflammation and fibrosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.34, 35, 36 In the recent ESSENCE trial, 62.9% of patients receiving semaglutide achieved resolution of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis at 72 weeks, compared to 34.3% in the placebo group (estimated treatment difference [ETD]: 28.7%, 95% CI 21.1, 36.2)

Diabetes and obesity are significant risk factors for morning hypertension: from Ibaraki Hypertension Assessment Trial (I-HAT)

Tirzepatide, at all three doses, was non-inferior and superior to semaglutide at 1 mg in achieving the primary endpoint of HbA1c reduction